ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2935

Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis

Barry J. Sheane1, Arane Thavaneswaran2, Dafna D. Gladman2 and Vinod Chandran2, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity, DMARDs, Outcome measures, psoriatic arthritis and remission

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis V - Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose

Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any, is not established. Randomized controlled trials examining the efficacy of MTX have been either under-powered or have used dosages that may be sub-optimal. While TNF inhibitors (TNFi) are used as second-line therapies in PsA, they have proven efficacy and disease-modifying effect. Minimal disease activity (MDA) is achieved at 24 weeks in 39% and 52% of patients treated with adalimumab and infliximab, respectively. There is a need to establish the treatment effect of MTX. An international task force recently recommended that disease remission or MDA be the target of treatment and should be attained within 6 months of initiating medication.

The aims of this retrospective study were to: a) establish the percentage of PsA patients that achieve MDA after 6 months of treatment with MTX, and b) identify the dose of MTX most likely to achieve MDA.

Methods

All patients attending a large, tertiary referral centre for PsA who initiated MTX and were naïve to biological medication on or after January 2004 up until April 2014 were assessed for inclusion. The primary outcome was the achievement of MDA after 6 months of MTX. MDA is defined as: the presence of at least 5 out of the following 7 domains: tender joint count ≤ 1, swollen joint count (SJC) ≤ 1, Psoriasis Area Severity Index (PASI) ≤ 1 or body surface area ≤ 3%, tender entheseal points ≤ 1, Health Assessment Questionnaire score ≤ 0.5, patient global disease activity Visual Analogue Scale (VAS) score ≤ 20 and patient pain VAS ≤ 15.

Of 204 patients identified, 29 had insufficient duration on MTX to accurately assess outcome. These were excluded, leaving 175 for analysis. Of these, 167 patients had sufficient data for analysis at 6 months.

Results

Of 204 patients, 54% were male. At the start of MTX use (all mean (SD)), age was 47.1 (13.5) years, duration of PsA 6.2 (8.0) years, PASI 5.5 (8.0), tender joint count 10.2 (10.7) and swollen joints 6.0 (7.4). Oral MTX was prescribed in 77.5%; 22 (10.8%) had been prescribed a DMARD in the past.

After 6 months on MTX, 29 patients (17.4%) achieved MDA, despite 97 patients (58.1%) achieving a SJC ≤ 1 and 138 (82.6%) a PASI ≤ 1; Patient-reported outcomes were less responsive, with only 22 (13.2%) achieving the outcome for disease activity. For patients achieving MDA, mean dose was 17.8 (4.2) mg/week by 6 months, with 58.6% taking ≥ 17.5 mg/week (76% were taking oral MTX). This dose was similar in those not achieving MDA. Back pain (both inflammatory and mechanical) and dactylitis were associated with a lower probability of achieving MDA.

Conclusion

Based on this analysis, MTX use achieves the recommended treatment target of MDA by 6 months in less than 20% of patients. This low rate of achievement is explained by failure of response in the patient-reported outcome components of the MDA criteria. Adequately-powered randomized controlled trials are needed to establish the efficacy of MTX as a first line drug in PsA.


Disclosure:

B. J. Sheane,
None;

A. Thavaneswaran,
None;

D. D. Gladman,
None;

V. Chandran,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/attainment-of-minimal-disease-activity-using-methotrexate-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology